Real World Data of Aflibercept in Wet AMD

Real World Data of Aflibercept in Wet AMD

Neovascular or wet age-related macular degeneration (AMD)
accounts for 10–15% of all cases of AMD. The prevalence of wet AMD
is rising and is expected to increase by one-third by 2020. Without
treatment, wet AMD leads to severe central vision loss. Anti-VEGF
agents such as aflibercept have become the mainstay of treatment
for wet AMD. Real world data from two large-scale UK audits show that
use of aflibercept in clinical practice stabilised or improved outcomes
in both treatment-naïve and pretreated patients with wet AMD.

Modern Medicine – July 2017